Hasegawa K, et al. – For ovarian, endometrial, and cervical cancers, the efficacy and safety of perifosine monotherapy were examined. Although expected efficacy was not achieved, perifosine monotherapy showed good tolerability. In ovarian cancer patients with PIK3CA mutations and endometrial cancer patients with PIK3CA wild–type, modest efficacy was demonstrated. There was no difference between PIK3CA wild–type and mutant in cervical cancer.